Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and they are evaluating next steps.

A combination Covid-flu vaccination developed by Pfizer Inc. and BioNTech SE missed on one of its goals in a final-stage trial, a disappointment for the companies trying to make further use of the technology that succeeded in the pandemic.

A combination shot including vaccines for both sicknesses failed to measure up in a Phase 3 trial, Pfizer said.

Pfizer and BioNTech said Friday that a Phase 3 trial of their COVID-19-and-influenza combination vaccine candidate met one of its two objectives.

Pfizer stock toppled Friday after the pharma giant reported mixed results for its BioNTech-partnered combination flu and Covid vaccine.

Pfizer and BioNTech’s Covid-19 and flu vaccine failed to meet a key goal in a late-stage trial, jeopardising a highly anticipated product that would help the drugmakers to compete in the post-Covid jab market.